AstraZeneca and Sputnik V Developer to Cooperate on COVID-19 Vaccine

British-Swedish vaccine manufacturer AstraZeneca has accepted an offer from Russia’s Gamaleya Institute on a cooperative study to determine if their two COVID-19 vaccine candidates can be successfully combined.

British-Swedish vaccine manufacturer AstraZeneca has accepted an offer from Russia’s Gamaleya Institute on a cooperative study to determine if their two COVID-19 vaccine candidates can be successfully combined.

“After the Sputnik V vaccine’s clinical trial preliminary results showed its efficacy at above 90 percent, the Russian Direct Investment Fund (RDIF, Russia’s sovereign wealth fund) and Gamaleya Institute on November 23, 2020, offered AstraZeneca to use one of the two components (human adenoviral vectors1) of the Sputnik V vaccine in AstraZeneca’s clinical trials”, announced the RDIF.

RDIF said that the clinical trials of AstraZeneca’s vaccine in combination with the Sputnik V would begin by the end of the month.

Gamaleya Research Institute Director Alexander Gintsburg claimed that the AztraZeneca vaccine is not efficient enough at its present state, but maybe improved with 2 components from the Sputnik V.

“Being able to combine different COVID-19 vaccines may be helpful to improved protection and/or to improve vaccine accessibility. This is why it is important to explore different vaccine combinations to help make immunization programmes more flexible, by allowing physicians greater choice at the time of administering vaccines,” commented AstraZeneca.

AstraZeneca has already applied for the approval of its vaccine in the UK but the Medicines and Healthcare products Regulatory Agency (MHRA) is still researching the data on the drug.


© Fourth Estate® — All Rights Reserved.
This material may not be published, broadcast, rewritten or redistributed.